Syros Pharmaceuticals (SYRS) Tops Q3 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. PTC
2. NVDA
3. PCVX
4. META
5. MSFT
6. SPY
7. GOOGL
8. GMAB
9. USO
10. AMD

Go back to Syros Pharmaceuticals (SYRS) Tops Q3 EPS by 1c

Syros Reports Third Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

November 12, 2019 8:00 AM EST

Presented New Clinical Data from Phase 2 Study of SY-1425 in RARA-Positive Newly Diagnosed Unfit AML Patients at ESH Conference

Presented New Preclinical Data on SY-5609 at AACR-NCI-EORTC Conference

On Track for Key 2020 Milestones, Including Potential Proof-of-Concept Data for SY-1425 in RARA-Positive Relapsed or Refractory AML and Initiation of Phase 1 Trial of SY-5609

Management to Host Conference Call at 8:30 a.m. ET Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in... More